跳至主要内容
临床试验/NCT03217201
NCT03217201已完成不适用

Systematic Light Exposure to Treat Cancer-Related Fatigue in Breast Cancer Patients

Icahn School of Medicine at Mount Sinai4 个研究点 分布在 1 个国家目标入组 194 人开始时间: 2018年1月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
194
试验地点
4
主要终点
FACIT-Fatigue Scale

研究概览

简要总结

Cancer related fatigue (CRF) is a stressful and constant tiredness related to cancer and/or its treatment. CRF is the most intense during treatment and can severely interfere with activities of daily living, such as tasks that require physical strength or thinking clearly. Prevalence of CRF has been reported to be as high as 94% during chemotherapy and as high as 34% five years after completion of treatment (Rotonda et al. 2013; Minton & Stone 2008). There is currently no generally-accepted treatment for CRF. However, there is evidence to suggest that light therapy can help with CRF. Non-pharmacological interventions for CRF have also been studied but are costly to implement and involve significant patient burden, particularly among those in active treatment. Given the clinical impact of CRF, the goal of this project is to investigate a novel, low-cost and low-burden intervention for Breast Cancer patients using a particular kind of light treatment called systematic light exposure (sLE) to treat CRF. Two hundred forty-eight breast cancer (BC) patients undergoing adjuvant or neoadjuvant chemotherapy will be recruited from Memorial Sloan Kettering Cancer Center, and City of Hope. The light will be administered by light glasses daily throughout entire duration of chemotherapy. Outcomes will be assessed at eight timepoints during chemo, and a series of follow up assessments at 1 week, 1-month, 3-months and 6-months post-chemotherapy. This study will have major public health relevance as it will determine if an easy-to-deliver, inexpensive, and low patient burden intervention effectively reduces CRF or prevents it from worsening during chemotherapy. Specific Aims: Aim 1: Determine if sLE prevents CRF from worsening in BC patients undergoing chemotherapy Aim 2: Determine whether sLE affects sleep, depression and circadian activity rhythms. Exploratory Aim 3: Investigate sLE normalizes circadian cortisol rhythms. Exploratory Aim 4: Examine whether the effects of sLE on fatigue are moderated/mediated by sleep quality, depression, and/or circadian rhythms.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Participant)

盲法说明

The participant does not know his or her study condition.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Newly diagnosed patients with stage 1 through 3a Breast Cancer scheduled to receive a 12-week, 16-week, 18-week, 20-week, or 24-week chemotherapy regimen, adjuvant, neoadjuvant, or already receiving chemotherapy.
  • MSH, COH and MSK can recruit participants schedule to go on aromatase inhibitors after treatment.
  • Currently over the age of
  • English language proficient.
  • Able to provide informed consent.

排除标准

  • Under age 18
  • Breast cancer patients scheduled to undergo chemo regimen other than the 12-week, 18-week, 20-week, or 24-week regimen
  • Stage 3B breast cancer inflammatory or Stage 4 breast cancer
  • Pregnancy
  • Currently employed in night shift work
  • Confounding underlying medical illnesses which may cause fatigue (e.g., severe Anemia not controlled by medication, per self-report corroborated by medical chart review (e.g., Hb<10gm/dl))
  • Eye Diseases which limit the ability of light to be processed (e.g., untreated cataracts, severe glaucoma, macular degeneration, blindness, pupil dilation problems or retina damage)
  • Secondary cancer diagnosis (prior or current) within the past 5 years
  • Severe sleep disorders (e.g., Narcolepsy)
  • Self- reported history of bipolar disorder or manic episodes (which is a contra-indication for light treatment)
  • Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months
  • Previous use of light therapy to alleviate fatigue or depressive symptoms
  • Lives outside of the United States throughout the duration of study

结局指标

主要结局

FACIT-Fatigue Scale

时间窗: up to 6 months

FACIT-Fatigue Scale - The FACIT-Fatigue scale will be used both for selection of patients into the study and as an outcome measure of fatigue. Smith et al. (1999) report that this 13 item scale has excellent test-retest reliability (r = 0.90) and internal consistency reliability (alpha = 0.93-0.95). In addition, criterion related validity studies using objective measures of physical function as the outcome show that patient reported fatigue based on the FACIT- Fatigue can predict these objective measures. This measure is the main tool for measuring fatigue in the Patient-Reported Outcomes Measurement Information System (PROMIS) initiative. Cella (personal communication) has indicated that a FACIT-Fatigue score equal to or less than 33 constitutes clinically significant fatigue.

次要结局

  • The Center for Epidemiological Studies Depression Scale (CES-D)(up to 6 months)
  • Credibility/Expectancy Questionnaire(up to 6 months)
  • Chronotype (MEQ)(up to 6 months)
  • The Pittsburgh Sleep Quality Index(up to 6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

William H. Redd

Professor

Icahn School of Medicine at Mount Sinai

研究点 (4)

Loading locations...

相似试验